Clinical trial
Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment…
NCT00351871 · Louisiana State University Health Sciences Center in New Orleans, Other · Completed
Key facts
| NCT number | NCT00351871 |
|---|---|
| Title | Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy |
| Official title | Influence of Marker of Insulin Resistance Upon HCV Treatment Responses to PEG Intron and Rebetol Therapy |
| Lead sponsor | Louisiana State University Health Sciences Center in New Orleans, Other |
| Collaborators | Schering-Plough Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | PEG-Intron Plus REBETOL |
| Enrollment | 400 |
| Start date | Apr 1, 2002 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Jul 13, 2006 |
| Last update posted | Feb 4, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: